Diabetes Metab J.  2011 Feb;35(1):8-11. 10.4093/dmj.2011.35.1.8.

New Perspectives on Diabetic Vascular Complications: The Loss of Endogenous Protective Factors Induced by Hyperglycemia

Affiliations
  • 1Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
  • 2Section on Vascular Cell Biology, Joslin Diabetes Center, Harvard University, Boston, MA, USA. George.King@joslin.harvard.edu

Abstract

Diabetic vascular complications are among the leading causes of morbidity and mortality in diabetic patients. In the past, many studies have focused on the mechanisms of hyperglycemia-induced chronic vascular complications via the formation of toxic metabolites such as oxidative stress, advanced glycosylated end products, persistent activation of protein kinase C, and increased sorbitol concentrations. However, vascular complications result from imbalances caused by increases in systemic toxic metabolites, such as those that occur under conditions of hyperglycemia and dyslipidemia, and by reductions in endogenous protective factors such as insulin, vascular endothelial growth factor, and platelet derived growth factor. This review outlines some of the evidence supporting the importance of enhancing endogenous regenerative factors.

Keyword

Diabetic vascular complication; Hyperglycemia; Platelet derived growth factor; Vascular endothelial growth factor

MeSH Terms

Diabetic Angiopathies
Dyslipidemias
Humans
Hyperglycemia
Insulin
Oxidative Stress
Platelet-Derived Growth Factor
Protein Kinase C
Sorbitol
Vascular Endothelial Growth Factor A
Insulin
Platelet-Derived Growth Factor
Protein Kinase C
Sorbitol
Vascular Endothelial Growth Factor A

Figure

  • Fig. 1 Diabetes induces an imbalance between toxic and protective factors to cause complications. FFA, free fatty acid; AGE, advanced glycosylated end product; ROS, reactive oxygen species; PKC, protein kinase C; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; APC, activated protein C.


Cited by  1 articles

Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial
Sanghoon Shin, Kwang-Joon Kim, In-Jeong Cho, Geu-Ru Hong, Yangsoo Jang, Namsik Chung, Young Min Rah, Hyuk-Jae Chang
Yonsei Med J. 2015;56(5):1227-1234.    doi: 10.3349/ymj.2015.56.5.1227.


Reference

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001. 414:813–820.
2. Enge M, Bjarnegard M, Gerhardt H, Gustafsson E, Kalen M, Asker N, Hammes HP, Shani M, Fassler R, Betsholtz C. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 2002. 21:4307–4316.
3. Yokota T, Ma RC, Park JY, Isshiki K, Sotiropoulos KB, Rauniyar RK, Bornfeldt KE, King GL. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes. 2003. 52:838–845.
4. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, Aiello LP, Kern TS, King GL. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009. 15:1298–1306.
5. Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG, Quaggin SE. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol. 2010. 21:1691–1701.
6. Ziyadeh FN. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res Clin Pract. 2008. 82:Suppl 1. S38–S41.
7. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008. 358:1129–1136.
8. He Z, Opland DM, Way KJ, Ueki K, Bodyak N, Kang PM, Izumo S, Kulkarni RN, Wang B, Liao R, Kahn CR, King GL. Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia. Arterioscler Thromb Vasc Biol. 2006. 26:787–793.
9. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007. 3:46–56.
10. Rask-Madsen C, Li Q, Freund B, Feather D, Abramov R, Wu IH, Chen K, Yamamoto-Hiraoka J, Goldenbogen J, Sotiropoulos KB, Clermont A, Geraldes P, Dall'Osso C, Wagers AJ, Huang PL, Rekhter M, Scalia R, Kahn CR, King GL. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab. 2010. 11:379–389.
11. Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Coney J, Orchard TJ, Aiello LP, King GL. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care. 2007. 30:1995–1997.
Full Text Links
  • DMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr